Company Filing History:
Years Active: 2025
Title: Michael V Mandola: Innovator in Cancer Treatment
Introduction
Michael V Mandola is a notable inventor based in Williamstown, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the area of non-small cell lung cancer (NSCLC). His innovative approach combines chemotherapy with targeted immunotherapy, showcasing his commitment to advancing medical science.
Latest Patents
Michael V Mandola holds a patent for "Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody." This patent outlines a method for treating patients afflicted with tumors derived from NSCLC. The method involves administering a combination of chemotherapy, an anti-PD-1 antibody or an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. Notably, the chemotherapy is administered for a period shorter than the standard treatment duration. He has 1 patent to his name.
Career Highlights
Michael is currently associated with Bristol-Myers Squibb Company, a leading biopharmaceutical company. His work focuses on developing innovative therapies that improve patient outcomes in oncology. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.
Collaborations
Michael has collaborated with esteemed colleagues, including Sabine Maier and Abderrahim Oukessou. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking treatments.
Conclusion
Michael V Mandola's contributions to cancer treatment through his innovative patent demonstrate his expertise and commitment to improving patient care. His work continues to inspire advancements in the field of oncology.